Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

Presentation ACC 2025

Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study

Presenter: Isabelle Mahé

March 29, 2025

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

Caitlin E. Cox

March 29, 2025

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

L.A. McKeown

November 26, 2024

News Opinion CV Team Dispatch

October 2023 News Roundup

L.A. McKeown

October 01, 2023

News Daily News

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

L.A. McKeown

June 29, 2022

News Opinion CV Team Dispatch

October 2021 News Roundup

L.A. McKeown

October 01, 2021

News Opinion CV Team Dispatch

July/August 2021 News Roundup

L.A. McKeown

August 01, 2021

News Daily News

Anticoagulation Use Quickly Rose to Meet COVID-19 Need

Caitlin E. Cox

June 14, 2021

News Features

The Right Anticoagulation Dose in COVID-19? Final Answer Remains Elusive

Todd Neale

February 08, 2021

News Daily News

ACC Issues New Guidance Around Antithrombotic Choices in A-fib, VTE

Todd Neale

December 22, 2020

News Daily News

Study Affirms Thrombotic Risk in COVID-19

Todd Neale

October 01, 2020

News Daily News

Heart, Kidneys, Brain, and More: COVID-19’s Wide-ranging Effects

Michael O'Riordan

July 13, 2020

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

L.A. McKeown

April 02, 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2018

Caitlin E. Cox

September 04, 2018

Presentation Aortovascular 2015

Novel Anticoagulants for Venous Thromboembolism: Will this change your practice?

Presenter: Michael R. Jaff

September 18, 2015

News Daily News

Similar Efficacy, Less Bleeding With Dabigatran vs. Warfarin in VTE Patients

Yael L. Maxwell

January 01, 2014

News Daily News

Eficacia Similar y Menos Hemorragias con Dabigatran que con Warfarina en Pacientes TEV

Yael L. Maxwell

January 01, 2014

News Daily News

Un Estudio de Imágenes ‘Punto de Referencia’ Socava la Hipótesis de las Anomalías Venosas en la EM

October 11, 2013

Advertisement

Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

November 2024 Dispatch for the CV Team

October 2023 News Roundup

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

October 2021 News Roundup

July/August 2021 News Roundup

Anticoagulation Use Quickly Rose to Meet COVID-19 Need

The Right Anticoagulation Dose in COVID-19? Final Answer Remains Elusive

ACC Issues New Guidance Around Antithrombotic Choices in A-fib, VTE

Study Affirms Thrombotic Risk in COVID-19

Heart, Kidneys, Brain, and More: COVID-19’s Wide-ranging Effects

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

TCTMD’s Top 10 Most Popular Stories for August 2018

Novel Anticoagulants for Venous Thromboembolism: Will this change your practice?

Similar Efficacy, Less Bleeding With Dabigatran vs. Warfarin in VTE Patients

Eficacia Similar y Menos Hemorragias con Dabigatran que con Warfarina en Pacientes TEV

Un Estudio de Imágenes ‘Punto de Referencia’ Socava la Hipótesis de las Anomalías Venosas en la EM

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content